Altered glucose metabolism is a common cancer phenotype. Because cancer cells and normal cells use metabolism differently, targeting this difference holds promise for improved cancer therapy. However, our understanding of how cancer cells incorporate nutrients into biomass to support growth and proliferation is based primarily on studies of cultured cells. Nutrient levels in culture differ substantially from those experienced by cells in tumors and these differences have a dramatic effect on metabolic phenotypes. Accordingly, we are using relevant mouse models of human cancer to examine the biochemical underpinnings of how glucose metabolism contributes to the initiation, growth, and progression of cancer. A key step in glucose metabolism is catalyzed by the glycolytic enzyme pyruvate kinase. Most mammalian cells express either the PKM1 or the alternatively spliced PKM2 isoform of this enzyme. PKM1 has high constitutive activity and favors the oxidation of glucose-derived pyruvate. Cancer cells universally express PKM2, which can adopt either an active or inactive state. Regulation of pyruvate kinase determines whether cells can synthesize enough nucleotides to proliferate, with low pyruvate kinase activity favoring a metabolic state that allows proliferation. This leads to several unanswered questions, including whether any pyruvate kinase is needed for tumor cell proliferation, how pyruvate kinase activity affects nucleotide synthesis, and how to practically use this information to improve cancer treatment. We are taking advantage of the fact that PKM1 expression and high pyruvate kinase activity is tumor suppressive to study how glucose metabolism affects nucleotide synthesis. By manipulating pyruvate kinase isoform expression or the availability of key metabolite precursors, we aim to determine the requirement for pyruvate kinase in cancer, and dissect how metabolism is altered by pyruvate kinase activity to affect nucleotide synthesis. For these studies we will take advantage of unique mouse models and small molecule drugs to manipulate tumor metabolism.
In Specific Aim 1, we will answer the question of whether pyruvate kinase is dispensable for proliferation in a tumor.
In Specific Aim 2, we will test the hypothesis that pyruvate kinase affects the redox state of cells, and that this is the mechanism by which pyruvate kinase isoform expression affects tumor metabolism and growth.
In Specific Aim 3 will perform preclinical studies in a prostate cancer model to determine how to use pyruvate kinase activators to treat patients. Together, these studies will advance our understanding of glucose metabolism and how it supports nucleotide synthesis and cancer progression. This work will also inform the design of future clinical trials and identify approaches to target metabolism for cancer therapy.

Public Health Relevance

Altered metabolism represents a fundamental difference between cancer cells and normal cells that is not well understood. This project combines mouse cancer models and small molecule drugs with state-of-the-art technology to interrogate metabolic pathway biochemistry. We strive to understand what products of metabolism are limiting for proliferation, and to define how glucose metabolism is regulated in cancer cells to produce key materials they need to divide. This work will inform how to target metabolism for cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA168653-06A1
Application #
9658233
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Spalholz, Barbara A
Project Start
2013-04-01
Project End
2023-11-30
Budget Start
2018-12-13
Budget End
2019-11-30
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Sullivan, Lucas B; Luengo, Alba; Danai, Laura V et al. (2018) Aspartate is an endogenous metabolic limitation for tumour growth. Nat Cell Biol 20:782-788
Hillis, Alissandra L; Lau, Allison N; Devoe, Camille X et al. (2018) PKM2 is not required for pancreatic ductal adenocarcinoma. Cancer Metab 6:17
Danai, Laura V; Babic, Ana; Rosenthal, Michael H et al. (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558:600-604
Muir, Alexander; Danai, Laura V; Vander Heiden, Matthew G (2018) Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies. Dis Model Mech 11:
Muir, Alexander; Vander Heiden, Matthew G (2018) The nutrient environment affects therapy. Science 360:962-963
Dayton, Talya L; Gocheva, Vasilena; Miller, Kathryn M et al. (2018) Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cancer Metab 6:6
Wyant, Gregory A; Abu-Remaileh, Monther; Wolfson, Rachel L et al. (2017) mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient. Cell 171:642-654.e12
Muir, Alexander; Danai, Laura V; Gui, Dan Y et al. (2017) Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. Elife 6:
Olenchock, Benjamin A; Rathmell, Jeffrey C; Vander Heiden, Matthew G (2017) Biochemical Underpinnings of Immune Cell Metabolic Phenotypes. Immunity 46:703-713
Mayers, Jared R; Vander Heiden, Matthew G (2017) Nature and Nurture: What Determines Tumor Metabolic Phenotypes? Cancer Res 77:3131-3134

Showing the most recent 10 out of 42 publications